In recent years, some immunotherapy, such as the programmed cell death protein 1(PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and the chimeric antigen receptors T cells (CAR-T), have achieved promising clinical therapeutic effects in cancer. Here, PDCD1 is linked to cancer.